Keapstone Therapeutics Limited, a single-asset virtual biotech with an innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s, announces that all drug discovery milestones have been successfully met in order to secure a further £1 million investment from Parkinson’s UK.

This brings the total seed investment in Keapstone to date...

Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with Selcia (part of Eurofins) and Cresset Discovery Services to create novel gene transcription modulators following excellent progress in the first 6 months of the project.  
 
In March 2018, Parkinson’s UK announced funding of £1.2million to create molecu...

Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
 
In January 2018, Parkinson’s UK announced funding of more than $1million in funding to enable the NLX-112 program to mo...

We're pleased to announce that Keapstone Therapeutics, a spin-out company formed as part of the Parkinson's Virtual Biotech, now has it's own independent website at www.keapstone.com.  

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor...

KEAPSTONE THERAPEUTICS was created in February 2017 as a single-asset virtual biotech company, spun out of University of Sheffield with seed funding of £1M provided by Parkinson’s UK.  Keapstone is dedicated to developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).  In...

A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today.

The collaboration, formed by leading charity Parkinson’s UK, contract innovation and research organization, Selcia (part of Eurofins), and computational chemistry software and services provider, Cresset Discovery Services, is centred on creating n...